Affinivax, Inc.
http://affinivax.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Affinivax, Inc.
GSK Spies Pfizer Challenge With $2.1bn Vaccine Company Acquisition
GSK has spotted an opportunity to challenge Pfizer’s blockbuster Prevnar franchise, but the potential of Affinivax’s platform has yet to be proven.
Keeping Track: Breakthroughs Of Summer Break Ground In Psychiatry, Cancer (Especially Nasopharygeal Cancer) And Vaccines
US FDA’s marquee expedited review program added 15 new breakthrough therapy designations between June and August.
Affinivax's 24-Valent Pneumococcal Vaccine Targets Growing And Changing Market
A potential next-generation, 24-valent, pneumococcal vaccine in development by Affinivax and Astellas has shown strong immunogenicity in a Phase II study and is preparing to enter pivotal Phase III trials; if successful, it will target a growing market currently dominated by big pharma players.
Finance Watch: Cell And Gene Therapy Firms Raised Nearly $20bn In 2020
Private Company Edition: Venture capital mega-rounds continue a brisk pace with machine learning-based drug discovery firm insitro and gene therapy developer Graphite Bio among recent $100m-plus deals. Also, Argobio raised €50m to fund five start-ups in Europe.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Vaccines